PL3727461T3 - Bicykliczne ligandy peptydowe swoiste wobec epha2 - Google Patents
Bicykliczne ligandy peptydowe swoiste wobec epha2Info
- Publication number
- PL3727461T3 PL3727461T3 PL18829926.7T PL18829926T PL3727461T3 PL 3727461 T3 PL3727461 T3 PL 3727461T3 PL 18829926 T PL18829926 T PL 18829926T PL 3727461 T3 PL3727461 T3 PL 3727461T3
- Authority
- PL
- Poland
- Prior art keywords
- epha2
- peptide ligands
- ligands specific
- bicyclic peptide
- bicyclic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1721259.8A GB201721259D0 (en) | 2017-12-19 | 2017-12-19 | Bicyclic peptide ligands specific for EphA2 |
| GBGB1804102.0A GB201804102D0 (en) | 2018-03-14 | 2018-03-14 | Bicycle peptide ligands specific for EphA2 |
| GBGB1818603.1A GB201818603D0 (en) | 2018-11-14 | 2018-11-14 | Bicyclic peptide ligands specific for epha2 |
| PCT/GB2018/053678 WO2019122863A1 (en) | 2017-12-19 | 2018-12-19 | Bicyclic peptide ligands specific for epha2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3727461T3 true PL3727461T3 (pl) | 2025-10-27 |
Family
ID=64902125
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22161978.6T PL4053145T3 (pl) | 2017-12-19 | 2018-12-19 | BICYKLICZNE LIGANDY PEPTYDOWE SWOISTE WOBEC EphA2 |
| PL18829926.7T PL3727461T3 (pl) | 2017-12-19 | 2018-12-19 | Bicykliczne ligandy peptydowe swoiste wobec epha2 |
| PL18829437.5T PL3727460T3 (pl) | 2017-12-19 | 2018-12-19 | Bicykliczne ligandy peptydowe swoiste wobec epha2 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22161978.6T PL4053145T3 (pl) | 2017-12-19 | 2018-12-19 | BICYKLICZNE LIGANDY PEPTYDOWE SWOISTE WOBEC EphA2 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18829437.5T PL3727460T3 (pl) | 2017-12-19 | 2018-12-19 | Bicykliczne ligandy peptydowe swoiste wobec epha2 |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US11484602B2 (pl) |
| EP (4) | EP4053145B1 (pl) |
| JP (4) | JP7404241B2 (pl) |
| KR (2) | KR102791088B1 (pl) |
| CN (4) | CN118598945A (pl) |
| AU (3) | AU2018387418B2 (pl) |
| BR (2) | BR112020012246A2 (pl) |
| CA (2) | CA3085253A1 (pl) |
| CY (1) | CY1125367T1 (pl) |
| DK (3) | DK4053145T3 (pl) |
| ES (3) | ES3037964T3 (pl) |
| FI (2) | FI4053145T3 (pl) |
| HR (2) | HRP20220871T1 (pl) |
| HU (1) | HUE059126T2 (pl) |
| IL (3) | IL275440B2 (pl) |
| LT (2) | LT3727460T (pl) |
| MX (2) | MX2020006482A (pl) |
| PH (1) | PH12020550929A1 (pl) |
| PL (3) | PL4053145T3 (pl) |
| PT (3) | PT3727461T (pl) |
| RS (1) | RS67248B1 (pl) |
| SA (1) | SA520412268B1 (pl) |
| SG (2) | SG11202005494QA (pl) |
| SI (2) | SI3727461T1 (pl) |
| SM (1) | SMT202500312T1 (pl) |
| TW (1) | TWI825046B (pl) |
| WO (2) | WO2019122863A1 (pl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017008575B1 (pt) | 2014-10-29 | 2021-07-13 | Bicyclerd Limited | Ligantes de peptídeos bicíclicos específicos a mt1-mmp, conjugado de fármaco, processo para preparação de um conjugado de fármaco e composição farmacêutica |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| CN110603261A (zh) | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | 具有新型键结构的肽衍生物 |
| CN111032678A (zh) | 2017-06-26 | 2020-04-17 | 拜西克尔德有限公司 | 具有可检测部分的双环肽配体和其用途 |
| CN118772242A (zh) | 2017-08-04 | 2024-10-15 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) * | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| BR112020014576A2 (pt) | 2018-02-23 | 2020-12-08 | Bicycletx Limited | Ligantes peptídicos bicíclicos multiméricos |
| SG11202009773VA (en) | 2018-04-04 | 2020-10-29 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| CN113474045A (zh) | 2018-12-21 | 2021-10-01 | 拜斯科技术开发有限公司 | Pd-l1特异性的双环肽配体 |
| CA3135569A1 (en) * | 2019-04-02 | 2020-10-08 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| JP2022532134A (ja) | 2019-05-09 | 2022-07-13 | バイスクルテクス・リミテッド | Ｏｘ４０に特異的な二環式ペプチドリガンド |
| TWI862640B (zh) * | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN114787197A (zh) * | 2019-08-13 | 2022-07-22 | 拜斯科技术开发有限公司 | 修饰的多聚双环肽配体 |
| DK4464721T3 (da) * | 2019-10-03 | 2025-07-21 | Bicycletx Ltd | Bicykliske heterotandem-peptidkomplekser |
| EP4065085A1 (en) * | 2019-11-27 | 2022-10-05 | BicycleTX Limited | Bicyclic peptide ligands specific for epha2 and uses thereof |
| CA3179152A1 (en) * | 2020-05-20 | 2021-11-25 | Amy Katherine DICKSON | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
| IL298868A (en) * | 2020-06-12 | 2023-02-01 | Bicycletx Ltd | Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2) |
| US20220031858A1 (en) * | 2020-08-03 | 2022-02-03 | Bicycle TX Limited | Novel linkers |
| AU2022206577A1 (en) | 2021-01-08 | 2023-08-24 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| US20250186539A2 (en) | 2021-01-11 | 2025-06-12 | Bicycletx Limited | Methods for treating cancer |
| CN117693519A (zh) | 2021-05-25 | 2024-03-12 | 瓦克斯细胞生物 | 基于单体拟抗体的嵌合抗原受体和包含其的免疫细胞 |
| MX2024002098A (es) * | 2021-08-17 | 2024-03-05 | Medshine Discovery Inc | Conjugado farmaco-polipeptido con estructura innovadora y su aplicacion. |
| KR20240082410A (ko) * | 2021-10-14 | 2024-06-10 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | EphA2 비시클릭 펩티드 리간드 및 이의 접합체 |
| KR20230140746A (ko) * | 2022-03-30 | 2023-10-10 | 연세대학교 산학협력단 | 암전이의 검출용 신규 바이오마커 |
| CN116063379B (zh) * | 2022-08-23 | 2025-05-02 | 中国药科大学 | EphA2靶向多肽及其应用 |
| WO2024184661A1 (en) | 2023-03-09 | 2024-09-12 | Bicycletx Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
| WO2024261490A1 (en) | 2023-06-23 | 2024-12-26 | Bicycletx Limited | Bicyclic peptide ligands specific for nk cells |
| WO2025191096A1 (en) * | 2024-03-14 | 2025-09-18 | Bicycletx Limited | Bicyclic peptide |
| CN119874840B (zh) * | 2025-03-31 | 2025-08-08 | 晶核生物医药科技(上海)有限公司 | 一种双环肽及其应用 |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| CA2345376C (en) | 1998-09-24 | 2010-03-16 | Advanced Research And Technology Institute, Inc. | Water-soluble luminescent quantum dots and bioconjugates thereof |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| GEP20053479B (en) | 1999-12-10 | 2005-03-25 | Pfizer Prod Inc | Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| DK3031910T3 (en) | 2002-02-21 | 2017-10-23 | Inst Virology | MN / CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED BY MN / CA IX-DEFICIENT MOUSE AND METHODS OF USE |
| BRPI0313733A8 (pt) | 2002-08-14 | 2016-08-16 | Atugen Ag | Uso da proteína n beta cinase |
| EP1852441B1 (en) * | 2002-09-24 | 2012-03-28 | The Burnham Institute | Agents that modulate EPH receptor activity |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| CA2518916A1 (en) | 2003-04-03 | 2004-10-21 | Joseph R. Garlich | Pi-3 kinase inhibitor prodrugs |
| CA2531069A1 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| JP2008504013A (ja) | 2004-02-06 | 2008-02-14 | モルフォシス・アクチェンゲゼルシャフト | 抗ｃｄ３８ヒト抗体及びその用途 |
| CA2505655C (en) | 2004-04-28 | 2013-07-09 | Warren Chan | Stable, water-soluble quantum dot, method of preparation and conjugates thereof |
| HRP20161751T1 (hr) | 2004-05-13 | 2017-04-07 | Icos Corporation | Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta |
| DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| JP5372380B2 (ja) | 2005-01-24 | 2013-12-18 | ペプスキャン システムズ ベー．フェー． | 結合化合物、免疫原性化合物およびペプチド模倣体 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| EP2364974A1 (en) | 2005-10-07 | 2011-09-14 | Exelixis, Inc. | N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors |
| MX362412B (es) | 2005-11-01 | 2019-01-15 | Targegen Inc | Inhibidores de biaril meta-pirimidina de cinasas. |
| ATE525374T1 (de) | 2005-12-13 | 2011-10-15 | Incyte Corp | Heteroarylsubstituierte pyrroloä2,3-büpyridine und pyrroloä2,3-büpyrimidine als januskinaseinhibitoren |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| PT2024372E (pt) | 2006-04-26 | 2010-09-16 | Hoffmann La Roche | Derivado de tieno[3,2-d]pirimidina útil como inibidor de pi3k |
| EA020324B1 (ru) * | 2006-07-18 | 2014-10-30 | Санофи-Авентис | АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ |
| US7666392B2 (en) | 2006-09-15 | 2010-02-23 | Siemens Medical Solutions Usa, Inc. | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| CN104030990B (zh) | 2007-03-12 | 2017-01-04 | Ym生物科学澳大利亚私人有限公司 | 苯基氨基嘧啶化合物及其用途 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| JP2010530437A (ja) | 2007-06-18 | 2010-09-09 | メディミューン，エルエルシー | ＥｐｈＡ２およびＥｒｂＢ２を発現する細胞の相乗的治療 |
| ES2509959T5 (en) | 2008-02-05 | 2024-12-19 | Bicyclerd Ltd | Methods and compositions |
| SG191660A1 (en) | 2008-03-11 | 2013-07-31 | Incyte Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
| WO2012057624A1 (en) | 2010-10-25 | 2012-05-03 | Pepscan Systems B.V. | Novel bicyclic peptide mimetics |
| GB201117428D0 (en) | 2011-10-07 | 2011-11-23 | Bicycle Therapeutics Ltd | Structured polypeptides with sarcosine linkers |
| SI3299377T1 (sl) | 2011-10-07 | 2021-07-30 | Bicyclerd Limited | Modulacija strukturirane specifičnosti polipeptida |
| KR101990341B1 (ko) | 2013-03-12 | 2019-06-19 | 몰레큘러 템플레이츠, 인코퍼레이션. | 세포 내재화를 유도하기 위한 ｃｄ20-결합 면역독소 및 이의 사용 방법 |
| US20140274759A1 (en) | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
| GB201306623D0 (en) | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
| US9868767B2 (en) | 2013-05-23 | 2018-01-16 | Ohio State Innovation Foundation | Chemical synthesis and screening of bicyclic peptide libraries |
| BR112016008996B1 (pt) | 2013-10-28 | 2023-01-24 | Bicyclerd Limited | Ligante peptídico específico para calicreína plasmática e composição farmacêutica |
| JP6875129B2 (ja) | 2014-05-08 | 2021-05-19 | ノボダイアックス， インコーポレイテッド | 直接的な免疫組織化学アッセイ |
| DK3149025T3 (da) | 2014-05-21 | 2019-07-22 | Entrada Therapeutics Inc | Cellepenetrerende peptider og fremgangsmåder til frembringelse og anvendelse deraf |
| BR112017008575B1 (pt) | 2014-10-29 | 2021-07-13 | Bicyclerd Limited | Ligantes de peptídeos bicíclicos específicos a mt1-mmp, conjugado de fármaco, processo para preparação de um conjugado de fármaco e composição farmacêutica |
| WO2016171242A1 (ja) | 2015-04-24 | 2016-10-27 | 第一三共株式会社 | Ｅｐｈａ２の検出 |
| WO2016174103A1 (en) * | 2015-04-28 | 2016-11-03 | Ecole polytechnique fédérale de Lausanne (EPFL) | Novel inhibitors of the enzyme activated factor xii (fxiia) |
| JP2019512477A (ja) | 2016-03-16 | 2019-05-16 | メリマック ファーマシューティカルズ インコーポレーティッド | エフリン受容体ａ２（ｅｐｈａ２）のナノリポソーム標的化及び関連する診断 |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| AU2017252233A1 (en) | 2016-04-22 | 2018-11-15 | Alligator Bioscience Ab | Novel bispecific polypeptides against CD137 |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| US10441663B2 (en) | 2016-11-27 | 2019-10-15 | Bicyclerd Limited | Methods for treating cancer |
| MX2019007367A (es) | 2016-12-23 | 2020-01-27 | Bicycletx Ltd | Ligandos de peptido para enlace a mt1-mmp. |
| CN110603261A (zh) | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | 具有新型键结构的肽衍生物 |
| ES2985986T3 (es) | 2017-01-06 | 2024-11-08 | Bicyclerd Ltd | Conjugado biciclo para tratar el cáncer |
| BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| GB201706477D0 (en) | 2017-04-24 | 2017-06-07 | Bicycle Therapeutics Ltd | Modification of polypeptides |
| US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| CN111032678A (zh) | 2017-06-26 | 2020-04-17 | 拜西克尔德有限公司 | 具有可检测部分的双环肽配体和其用途 |
| CN118772242A (zh) | 2017-08-04 | 2024-10-15 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| US20200291096A1 (en) | 2017-08-14 | 2020-09-17 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| EP3668550A1 (en) | 2017-08-14 | 2020-06-24 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
| CN117252247A (zh) * | 2017-09-20 | 2023-12-19 | 视觉动力公司 | 传感器-显示设备 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| US11572370B2 (en) | 2018-01-08 | 2023-02-07 | Biohaven Therapeutics Ltd. | CD16A binding agents and uses thereof |
| BR112020014576A2 (pt) | 2018-02-23 | 2020-12-08 | Bicycletx Limited | Ligantes peptídicos bicíclicos multiméricos |
| SG11202009773VA (en) | 2018-04-04 | 2020-10-29 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes |
| JP2021525243A (ja) | 2018-05-21 | 2021-09-24 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | Ｎｋ細胞による標的細胞の殺傷を増進するための組成物および方法 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| WO2020120984A1 (en) | 2018-12-13 | 2020-06-18 | Bicycletx Limited | Bicyclic peptide ligands specific for mt1-mmp |
| US11702482B2 (en) | 2018-12-17 | 2023-07-18 | Revitope Limited | Twin immune cell engager |
| CN113474045A (zh) | 2018-12-21 | 2021-10-01 | 拜斯科技术开发有限公司 | Pd-l1特异性的双环肽配体 |
| CA3135569A1 (en) | 2019-04-02 | 2020-10-08 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| JP2022532134A (ja) | 2019-05-09 | 2022-07-13 | バイスクルテクス・リミテッド | Ｏｘ４０に特異的な二環式ペプチドリガンド |
| TWI862640B (zh) | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN114787197A (zh) | 2019-08-13 | 2022-07-22 | 拜斯科技术开发有限公司 | 修饰的多聚双环肽配体 |
| DK4464721T3 (da) | 2019-10-03 | 2025-07-21 | Bicycletx Ltd | Bicykliske heterotandem-peptidkomplekser |
| EP4065085A1 (en) | 2019-11-27 | 2022-10-05 | BicycleTX Limited | Bicyclic peptide ligands specific for epha2 and uses thereof |
| IL298868A (en) | 2020-06-12 | 2023-02-01 | Bicycletx Ltd | Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2) |
| MX2023001588A (es) | 2020-08-17 | 2023-05-03 | Bicycletx Ltd | Conjugados biciclo específicos para nectina-4 y usos de estos. |
| AU2022206577A1 (en) | 2021-01-08 | 2023-08-24 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| US20250186539A2 (en) | 2021-01-11 | 2025-06-12 | Bicycletx Limited | Methods for treating cancer |
-
2018
- 2018-12-11 TW TW107144453A patent/TWI825046B/zh active
- 2018-12-14 US US16/220,685 patent/US11484602B2/en active Active
- 2018-12-19 IL IL275440A patent/IL275440B2/en unknown
- 2018-12-19 SG SG11202005494QA patent/SG11202005494QA/en unknown
- 2018-12-19 AU AU2018387418A patent/AU2018387418B2/en active Active
- 2018-12-19 PT PT188299267T patent/PT3727461T/pt unknown
- 2018-12-19 WO PCT/GB2018/053678 patent/WO2019122863A1/en not_active Ceased
- 2018-12-19 HR HRP20220871TT patent/HRP20220871T1/hr unknown
- 2018-12-19 HU HUE18829437A patent/HUE059126T2/hu unknown
- 2018-12-19 WO PCT/GB2018/053675 patent/WO2019122860A1/en not_active Ceased
- 2018-12-19 ES ES18829926T patent/ES3037964T3/es active Active
- 2018-12-19 SI SI201831253T patent/SI3727461T1/sl unknown
- 2018-12-19 FI FIEP22161978.6T patent/FI4053145T3/fi active
- 2018-12-19 MX MX2020006482A patent/MX2020006482A/es unknown
- 2018-12-19 PT PT221619786T patent/PT4053145T/pt unknown
- 2018-12-19 LT LTEPPCT/GB2018/053675T patent/LT3727460T/lt unknown
- 2018-12-19 AU AU2018387417A patent/AU2018387417C9/en active Active
- 2018-12-19 CN CN202410627078.XA patent/CN118598945A/zh active Pending
- 2018-12-19 EP EP22161978.6A patent/EP4053145B1/en active Active
- 2018-12-19 DK DK22161978.6T patent/DK4053145T3/da active
- 2018-12-19 MX MX2020006474A patent/MX2020006474A/es unknown
- 2018-12-19 IL IL321490A patent/IL321490A/en unknown
- 2018-12-19 FI FIEP18829926.7T patent/FI3727461T3/fi active
- 2018-12-19 EP EP18829926.7A patent/EP3727461B1/en active Active
- 2018-12-19 CN CN202410970988.8A patent/CN118909043A/zh active Pending
- 2018-12-19 ES ES18829437T patent/ES2922632T3/es active Active
- 2018-12-19 JP JP2020534361A patent/JP7404241B2/ja active Active
- 2018-12-19 CN CN201880089662.7A patent/CN111787955B/zh active Active
- 2018-12-19 ES ES22161978T patent/ES2987839T3/es active Active
- 2018-12-19 SI SI201830718T patent/SI3727460T1/sl unknown
- 2018-12-19 HR HRP20251070TT patent/HRP20251070T1/hr unknown
- 2018-12-19 BR BR112020012246-7A patent/BR112020012246A2/pt unknown
- 2018-12-19 PL PL22161978.6T patent/PL4053145T3/pl unknown
- 2018-12-19 CN CN201880089757.9A patent/CN111741771B/zh active Active
- 2018-12-19 SM SM20250312T patent/SMT202500312T1/it unknown
- 2018-12-19 CA CA3085253A patent/CA3085253A1/en active Pending
- 2018-12-19 DK DK18829437.5T patent/DK3727460T3/da active
- 2018-12-19 LT LTEPPCT/GB2018/053678T patent/LT3727461T/lt unknown
- 2018-12-19 PL PL18829926.7T patent/PL3727461T3/pl unknown
- 2018-12-19 KR KR1020207019676A patent/KR102791088B1/ko active Active
- 2018-12-19 KR KR1020207019675A patent/KR102890185B1/ko active Active
- 2018-12-19 SG SG11202005495UA patent/SG11202005495UA/en unknown
- 2018-12-19 EP EP18829437.5A patent/EP3727460B1/en active Active
- 2018-12-19 BR BR112020012349-8A patent/BR112020012349A2/pt unknown
- 2018-12-19 CA CA3086257A patent/CA3086257A1/en active Pending
- 2018-12-19 PT PT188294375T patent/PT3727460T/pt unknown
- 2018-12-19 US US16/771,186 patent/US11696956B2/en active Active
- 2018-12-19 JP JP2020534623A patent/JP7293231B2/ja active Active
- 2018-12-19 RS RS20250881A patent/RS67248B1/sr unknown
- 2018-12-19 PL PL18829437.5T patent/PL3727460T3/pl unknown
- 2018-12-19 EP EP25169487.3A patent/EP4582436A3/en active Pending
- 2018-12-19 DK DK18829926.7T patent/DK3727461T3/da active
-
2020
- 2020-06-17 IL IL275437A patent/IL275437B2/en unknown
- 2020-06-17 PH PH12020550929A patent/PH12020550929A1/en unknown
- 2020-06-18 SA SA520412268A patent/SA520412268B1/ar unknown
-
2022
- 2022-07-12 CY CY20221100481T patent/CY1125367T1/el unknown
- 2022-09-23 US US17/934,896 patent/US11833211B2/en active Active
-
2023
- 2023-05-08 US US18/313,983 patent/US20240000957A1/en active Pending
- 2023-06-07 JP JP2023093890A patent/JP7503689B2/ja active Active
- 2023-11-01 US US18/499,739 patent/US20240189436A1/en active Pending
-
2024
- 2024-04-22 AU AU2024202618A patent/AU2024202618A1/en active Pending
- 2024-06-10 JP JP2024093609A patent/JP2024138253A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275437A (en) | EPHA2-specific bicyclic peptide ligands | |
| ZA202100442B (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201721265D0 (en) | Bicyclic peptide ligands specific for EphA2 | |
| GB201820320D0 (en) | Bicyclic peptide ligands specific for FAPalpha | |
| GB201721259D0 (en) | Bicyclic peptide ligands specific for EphA2 | |
| GB201707734D0 (en) | Bicyclic peptide ligands specific for EphA2 | |
| GB201818603D0 (en) | Bicyclic peptide ligands specific for epha2 | |
| GB201720934D0 (en) | Bicyclic peptide ligands specific for FAPalpha | |
| GB201712693D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201818499D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201815684D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB201720941D0 (en) | Bicyclic peptide ligands specific for EPHA3 | |
| GB201720932D0 (en) | Bicyclic peptide ligands specific for IL-17 | |
| GB201621574D0 (en) | Bicyclic peptide ligands specific for fapalpha | |
| GB201810321D0 (en) | Peptide ligands for bindingto EphA2 | |
| GB201720928D0 (en) | Bicyclic peptide ligands specific for IL-6 | |
| GB201720933D0 (en) | Bicyclic peptide ligands specific for cathepsin G | |
| GB201701834D0 (en) | Bicyclic peptide ligands specific for CD38 | |
| GB201720940D0 (en) | Bicyclic peptide ligands specific for PSMA | |
| GB201715621D0 (en) | Bicycle peptide ligands specific for EphA2 | |
| GB201720926D0 (en) | Bicyclic peptide ligands specific for chymase | |
| GB201720939D0 (en) | Bicyclic peptide ligands specific for VEGF | |
| GB201720936D0 (en) | Bicyclic peptide ligands specific for TGFbeta | |
| GB201712589D0 (en) | Bicyclic peptide ligands specific for CD137 | |
| GB201720938D0 (en) | Bicyclic peptide ligands specific for TNFalpha |